Featured Image

Why is it important?

The definitions of RAI refractory disease are valid for the thyroid cancer patients treated with lenvatinib.

Read the Original

This page is a summary of: Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial, Thyroid, September 2017, Mary Ann Liebert Inc,
DOI: 10.1089/thy.2016.0549.
You can read the full text:

Read

Contributors

The following have contributed to this page